Complete Guide to Specialty Cancer Medicines in the Philippines (2026)
Cancer treatment in the Philippines has reached an inflection point. Medicines that were once available only to patients in the United States or Europe — targeted therapies, immunotherapies, antibody-drug conjugates — are now accessible to Filipino patients willing to navigate the specialty import pathway.
This guide is the most comprehensive resource available for Filipino patients, caregivers, and oncologists seeking to understand the landscape of specialty cancer medicines in the Philippines: what they are, how they work, how to access them, and how to make them affordable.
What Are Specialty Cancer Medicines?
Specialty cancer medicines are a category of treatments that differ fundamentally from traditional chemotherapy drugs. While chemotherapy works by killing all rapidly dividing cells (cancerous and healthy alike), specialty cancer medicines are designed to target specific molecular features of cancer cells — minimising damage to healthy tissue while precisely attacking the tumour.
Characteristics of specialty medicines:
– Target specific genetic mutations, proteins, or pathways in cancer cells
– Often require biomarker testing before use (e.g., EGFR, HER2, PD-L1, BRCA)
– Generally taken as oral tablets or IV infusions
– Dramatically more expensive than traditional chemotherapy
– Often produce higher response rates and fewer severe side effects than chemo
These medicines represent the future — and increasingly the present — of cancer treatment. The Philippine oncology community is actively adopting international treatment guidelines that centre these medicines.
Major Classes of Specialty Cancer Medicines
1. Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs)
TKIs block specific enzymes (kinases) that cancer cells use to grow and multiply. They are among the most widely used specialty cancer medicines.
Subclasses available in Philippines:
EGFR Inhibitors (for NSCLC with EGFR mutations):
– 1st gen: Erlotinib (Tarceva), Gefitinib (Iressa)
– 2nd gen: Afatinib (Gilotrif / Afanat)
– 3rd gen: Osimertinib (Tagrisso) — current standard of care
ALK/ROS1 Inhibitors (for NSCLC with ALK/ROS1 rearrangements):
– Crizotinib (Xalkori), Alectinib (Alecensa), Ceritinib (Zykadia)
BCR-ABL Inhibitors (for chronic myeloid leukemia / CML):
– Imatinib (Gleevec), Dasatinib (Sprycel), Nilotinib (Tasigna)
– Imatinib generics are now affordable in Philippines
BTK Inhibitors (for blood cancers — CLL, MCL):
– Ibrutinib (Imbruvica), Acalabrutinib (Calquence)
CDK4/6 Inhibitors (for HR+/HER2- advanced breast cancer):
– Palbociclib (Ibrance), Ribociclib (Kisqali), Abemaciclib (Verzenio)
VEGF/VEGFR Inhibitors (anti-angiogenic — starve tumour blood supply):
– Bevacizumab (Avastin) — multiple cancers
– Lenvatinib (Lenvima / Lenvat) — thyroid, liver, kidney, endometrial
– Sorafenib (Nexavar) — liver, thyroid, kidney cancer
– Sunitinib (Sutent) — kidney, GIST, pancreatic NET
2. Monoclonal Antibodies
Monoclonal antibodies are laboratory-engineered proteins designed to attach to specific targets on cancer cells, either directly destroying them or flagging them for destruction by the immune system.
Key monoclonal antibodies available:
| Medicine | Brand | Target | Cancer Types |
|---|---|---|---|
| Trastuzumab | Herceptin | HER2 | Breast cancer, gastric cancer |
| Bevacizumab | Avastin | VEGF | Colorectal, lung, cervical, ovarian |
| Rituximab | Mabthera | CD20 | NHL, CLL |
| Cetuximab | Erbitux | EGFR | Colorectal, head & neck |
| Pembrolizumab | Keytruda | PD-1 | Multiple cancers |
| Nivolumab | Opdivo | PD-1 | Multiple cancers |
Most monoclonal antibodies are IV-administered at hospital infusion centres. Biosimilars (biologically equivalent but lower-cost versions) exist for Trastuzumab, Bevacizumab, and Rituximab — making these more accessible.
3. Immunotherapy: Checkpoint Inhibitors
Immune checkpoint inhibitors remove the “brakes” that cancer cells place on the immune system, allowing the body’s own defences to attack the tumour.
How they work: Cancer cells express proteins like PD-L1 that bind to PD-1 receptors on T-cells, preventing the immune system from recognising and attacking them. Checkpoint inhibitors block this interaction.
Types:
– PD-1 inhibitors: Pembrolizumab (Keytruda), Nivolumab (Opdivo)
– PD-L1 inhibitors: Atezolizumab (Tecentriq), Durvalumab (Imfinzi)
– CTLA-4 inhibitors: Ipilimumab (Yervoy) — used in combination
Cancer types benefiting from checkpoint inhibitors in Philippines:
– Non-small cell lung cancer (NSCLC) — especially PD-L1 high
– Melanoma
– Gastric/gastroesophageal cancer
– Triple-negative breast cancer (with chemotherapy)
– Cervical cancer
– Colorectal cancer (MSI-high)
– Hepatocellular carcinoma (liver cancer)
Pembrolizumab testing requires PD-L1 IHC testing and sometimes MSI/TMB testing — ask your oncologist.
4. Hormone Therapy
For hormone-sensitive cancers (HR+ breast cancer, prostate cancer), hormone therapy removes or blocks the hormones that fuel cancer growth.
Breast cancer:
– Tamoxifen — widely available, affordable
– Aromatase inhibitors: Letrozole, Anastrozole, Exemestane — widely available
– Fulvestrant (Faslodex) — specialty import via Pinoymeds
Prostate cancer:
– LHRH agonists: Leuprolide, Goserelin — ADT (androgen deprivation therapy)
– Anti-androgens: Bicalutamide — affordable
– Novel agents: Abiraterone (Zytiga / Abirapro), Enzalutamide (Xtandi) — specialty import via Pinoymeds
5. PARP Inhibitors
PARP inhibitors target cancer cells with deficient DNA repair mechanisms (particularly BRCA1/2-mutated cancers).
Available:
– Olaparib (Lynparza) — breast cancer (BRCA+), ovarian cancer, prostate cancer (BRCA+)
– Niraparib (Zejula) — ovarian cancer
– Talazoparib (Talzenna) — breast cancer (BRCA+)
Requires BRCA testing. Available through Pinoymeds specialty import pathway.
6. Antibody-Drug Conjugates (ADCs)
ADCs combine a monoclonal antibody (targeting a cancer cell surface protein) with a potent chemotherapy payload. They deliver chemotherapy precisely to cancer cells, reducing systemic toxicity.
Examples:
– Ado-Trastuzumab Emtansine / T-DM1 (Kadcyla) — HER2+ breast cancer
– Trastuzumab Deruxtecan / T-DXd (Enhertu) — HER2+ and HER2-low breast cancer
– Sacituzumab Govitecan (Trodelvy) — triple-negative breast cancer, urothelial cancer
ADCs are the fastest-growing class of oncology medicines globally. Available through specialist import via Pinoymeds — contact us for availability.
Cancer Types and Their Specialty Medicine Landscape
| Cancer Type | Key Biomarker Tests | Specialty Medicines Used | Pinoymeds Availability |
|---|---|---|---|
| NSCLC (Lung) | EGFR, ALK, ROS1, PD-L1 | TKIs, checkpoint inhibitors | ✅ Full range |
| Breast cancer | ER/PR, HER2, BRCA | CDK4/6 inhibitors, anti-HER2, PARP inhibitors | ✅ Full range |
| Prostate cancer | AR, BRCA | Abiraterone, Enzalutamide, PARP inhibitors | ✅ Full range |
| Liver cancer (HCC) | — | Sorafenib, Lenvatinib, checkpoint inhibitors | ✅ Available |
| Blood cancer (CML) | BCR-ABL | Imatinib, Dasatinib, Nilotinib | ✅ Available |
| Blood cancer (CLL) | — | Ibrutinib, Acalabrutinib, Venetoclax | ✅ Available |
| Kidney cancer (RCC) | — | Sunitinib, Pazopanib, checkpoint inhibitors | ✅ Available |
| Colorectal cancer | RAS, MSI | Cetuximab, checkpoint inhibitors | Contact us |
| Cervical cancer | PD-L1 | Pembrolizumab + chemo | Contact us |
Biomarker Testing: The Essential First Step
For most specialty cancer medicines, you need biomarker testing before you can be prescribed the right treatment. Biomarker testing determines which specific targeted therapy you will respond to.
Common tests and where to get them in Philippines:
| Test | Purpose | Where Available | Cost |
|---|---|---|---|
| EGFR mutation (tissue/liquid) | Lung cancer targeted therapy | PGH, SLMC, MakMed, The Medical City | ₱15,000–₱40,000 |
| ALK/ROS1 (FISH or IHC) | Lung cancer ALK TKI | Major oncology hospitals | ₱10,000–₱25,000 |
| HER2 (IHC + FISH) | Breast/gastric anti-HER2 therapy | All oncology hospitals | ₱5,000–₱15,000 |
| BRCA1/2 germline | Breast, ovarian, prostate PARP inhibitors | Select labs | ₱15,000–₱35,000 |
| PD-L1 IHC | Checkpoint inhibitor eligibility | Major oncology hospitals | ₱8,000–₱20,000 |
| MSI/MMR | Colorectal checkpoint inhibitor | Select labs | ₱10,000–₱25,000 |
| PIK3CA mutation | Alpelisib in HR+ breast cancer | Select labs | ₱15,000–₱30,000 |
Always get testing done before starting treatment — not after. The right test prevents expensive trial-and-error.
How to Access Specialty Cancer Medicines in the Philippines
The Import Pathway (via Pinoymeds)
Most specialty cancer medicines are not stocked at community pharmacies in the Philippines. They must be imported through a formal process:
- Get diagnosis and prescription from your Philippine oncologist
- Contact Pinoymeds — submit your prescription and enquiry
- FDA Compassionate Special Permit — Pinoymeds handles the application
- Medicine sourced and delivered — to your home, nationwide
Timeline: typically 3–6 weeks from enquiry to first delivery.
Hospital Pharmacy Channels
Some specialty medicines are available directly through hospital pharmacies at major tertiary care centres (Philippine General Hospital, St. Luke’s Medical Center, Makati Medical Center, The Medical City, National Kidney and Transplant Institute).
Availability varies and waiting lists can be long. Pinoymeds often offers faster access and better pricing, especially for generics.
Affordability: Branded vs Generic Specialty Medicines
The cost of branded specialty cancer medicines is prohibitive for most Filipino families. Generic versions — containing the identical active ingredient, manufactured to international quality standards — offer the same clinical benefit at dramatically lower cost.
Pinoymeds generic pricing (indicative, per month):
| Medicine | Branded Price | Generic via Pinoymeds | Savings |
|---|---|---|---|
| Osimertinib (Tagrisso) | ₱350,000–₱450,000 | ₱25,000–₱50,000 | ~93% |
| Palbociclib (Ibrance) | ₱200,000–₱300,000 | ₱18,000–₱35,000 | ~91% |
| Afatinib (Gilotrif) | ₱150,000–₱220,000 | ₱12,000–₱25,000 | ~92% |
| Lenvatinib (Lenvima) | ₱200,000–₱280,000 | ₱20,000–₱40,000 | ~90% |
| Abiraterone (Zytiga) | ₱120,000–₱180,000 | ₱10,000–₱20,000 | ~89% |
All Pinoymeds generics are sourced from FDA/EMA-certified manufacturers with full quality documentation.
Combining Assistance Sources
Filipino patients can combine multiple financial assistance mechanisms:
| Source | What It Covers | How to Access |
|---|---|---|
| Generic medicines (Pinoymeds) | 89–93% cost reduction | Contact Pinoymeds directly |
| PCSO Medical Assistance | Partial-full medicine cost | Apply at PCSO or hospital social work |
| PhilHealth Z Benefit | Specific cancer types | Through treating hospital |
| Malasakit Centers | Combined government assistance | At major government hospitals |
| Manufacturer PAPs | Case-by-case for branded | Ask your oncologist |
Many patients successfully combine 2–3 of these sources to achieve fully sustainable treatment.
Pinoymeds’ Specialty Medicine Catalogue
Pinoymeds carries 408+ specialty medicines across all major cancer categories:
- Oncology: Blood cancer, breast cancer, kidney cancer, liver cancer, lung cancer, prostate cancer, ovarian cancer, colorectal cancer, cervical cancer
- Hepatology: Hepatitis B and C medicines
- HIV/AIDS: Antiretroviral therapy
- Sexual Wellness: Erectile dysfunction and female sexual dysfunction medicines
- Rare Diseases: Select medicines for rare conditions
All medicines in our catalogue come with:
– Valid FDA import documentation
– Certificate of analysis and batch traceability
– Transparent pricing with no hidden charges
– Home delivery nationwide across the Philippines
Free Consultation with a Filipino Oncologist
Not sure which medicine you need, or want a second opinion on your treatment plan? Pinoymeds offers free consultations with Filipino oncologists through our network of 170+ doctors.
Consultations are conducted online (video call, Viber, WhatsApp) and are free of charge. Our doctors can review your pathology report, biomarker test results, and current treatment plan.
Frequently Asked Questions
Q: What is the difference between a specialty medicine and a regular medicine?
A: Specialty medicines are typically targeted biologics or small molecules requiring specific biomarker eligibility, special handling or administration, and often specialty import processes. They tend to be significantly more expensive but more precisely effective than traditional medicines.
Q: Do I need a prescription for specialty cancer medicines in Philippines?
A: Yes. All prescription oncology medicines require a valid prescription from a licensed Philippine physician. Pinoymeds does not supply medicines without a prescription.
Q: How long does it take to receive my first order?
A: Typically 3–6 weeks from first enquiry, including FDA permit processing. Urgent cases may be expedited. Medicines we have in stock can sometimes be dispatched faster.
Q: Are generic specialty medicines as effective as branded?
A: Yes, when sourced from reputable FDA/EMA-certified manufacturers. The active ingredient, dose, and formulation are identical. Pinoymeds sources exclusively from verified manufacturers.
Q: My oncologist prescribed a medicine not in your catalogue. Can you source it?
A: Very often yes — contact us. Our sourcing network covers most specialty oncology medicines globally.
Q: Can I order medicine for a family member?
A: Yes, with their valid prescription and consent documentation.
Start Your Journey with Pinoymeds
Pinoymeds was built for Filipino patients who deserve the same access to life-saving specialty medicines as patients in any other country. We handle the complexity — permits, sourcing, customs, delivery — so you can focus on treatment and recovery.
Contact us today:
– 💬 WhatsApp / Viber / Telegram — message anytime, 24/7 support
– 🩺 Free oncologist consultation — available online
– 💊 Browse our 408-medicine catalogue at pinoymeds.ph
This guide is for educational purposes. Always consult your licensed physician for personalised treatment advice.